- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Fr | OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 283 | Newsfile | Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation &... ► Artikel lesen | |
| 10.10. | OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate | 2 | Benzinga.com | ||
| 10.10. | OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma | 249 | Newsfile | 75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p 100% of patients who achieved 12 month event free survival achieved 2 year overall... ► Artikel lesen | |
| 09.10. | OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting | 222 | Newsfile | Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma... ► Artikel lesen | |
| 07.10. | OS Therapies to Participate in Fall 2025 Conferences and Events | 234 | Newsfile | Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated... ► Artikel lesen | |
| 30.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | OS Therapies Updates Sequence Of OST-HER2 Regulatory Submissions, Prioritizes UK MHRA MAA Submission | 1 | RTTNews | ||
| 30.09. | OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update | 207 | Newsfile | Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting... ► Artikel lesen | |
| 19.09. | OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT | 236 | Newsfile | New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 12.09. | OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit | 264 | Newsfile | Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention... ► Artikel lesen | |
| 03.09. | OS Therapies to Participate in Upcoming Investor Conferences in September 2025 | 274 | Newsfile | New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 02.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting | 298 | Newsfile | Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp.... ► Artikel lesen | |
| 02.09. | OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing | 399 | Newsfile | All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparationsNew... ► Artikel lesen | |
| 27.08. | OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 | 362 | Newsfile | New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 26.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | OS Therapies Terminates Equity Line of Credit | 390 | Newsfile | New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 19.08. | OS Therapies reports Q2 results | 10 | Seeking Alpha | ||
| 19.08. | OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update | 488 | Newsfile | U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 59,00 | -0,84 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| IMMUNIC | 0,692 | +0,87 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,110 | -0,47 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 7,790 | +1,30 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program | ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,660 | -4,88 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| ZEVRA THERAPEUTICS | 9,400 | +1,62 % | Zevra Therapeutics stock maintains Overweight rating at Cantor Fitzgerald | ||
| PROTALIX BIOTHERAPEUTICS | 1,610 | +1,26 % | Why Is Protalix BioTherapeutics Stock Falling On Friday? | ||
| GEOVAX LABS | 0,556 | -1,16 % | GeoVax Labs files to sell 11.9M shares of common stock for holders | ||
| SCILEX | 12,790 | -3,87 % | Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase | PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,810 | -2,95 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| MEIRAGTX | 6,800 | -1,45 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| INVIVYD | 1,735 | -0,86 % | Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID | The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 4,720 | -4,26 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease | LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
| QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,025 (-1,34 %) liegt der Kurs bei 1,845 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.